Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasms by Histologic Type × olaparib × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 37 Ovarian Neoplasms 31 Prostatic Neoplasms 18 Triple Negative Breast Neoplasms 16 Fallopian Tube Neoplasms 16 Neoplasm Metastasis 11 Neoplasms 9 Pancreatic Neoplasms 8 Endometrial Neoplasms 8 Small Cell Lung Carcinoma 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Carcinoma, Non-Small-Cell Lung 6 Stomach Neoplasms 5 Sarcoma 5 Glioma 5 Lung Neoplasms 4 Glioblastoma 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Metastatic Castration-resistant Prostate Cancer 3 Lymphoma, Non-Hodgkin 3 Cholangiocarcinoma 3 Carcinoma, Ovarian Epithelial 3 Urinary Bladder Neoplasms 2 Solid Tumors 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Peritoneal Neoplasms 2 Pathologic Complete Response 2 Osteosarcoma 2

Interventions

fludarabine 4 Cisplatin 4 Pemetrexed 3 Cyclophosphamide 3 pralsetinib 2 pembrolizumab 2 fludarabine phosphate 2 durvalumab 2 cobimetinib 2 atezolizumab 2 Whole-Body Irradiation 2 Vemurafenib 2 Tacrolimus 2 Peripheral Blood Stem Cell Transplantation 2 Patient Reported Outcome Measures 2 Paclitaxel 2 Nivolumab 2 Mycophenolic Acid 2 Mesna 2 Melphalan 2 Busulfan 2 130-nm albumin-bound paclitaxel 2 trametinib 1 spartalizumab 1 ruxolitinib 1 repotrectinib 1 ponatinib 1 pertuzumab 1 gilteritinib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡